IASLC 18th World Conference on Lung Cancer
October 15-18 marked the annual International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC). Oncologists from over 100 countries came together in Yokohama, Japan to discuss the latest developments and findings related to thoracic malignancy research. Journal of Clinical Pathways highlights some of the most relevant discussions from this meeting.
A recent study compared the effectiveness of stereotactic ablative body radiotherapy with conventional full fractionated radiotherapy in prolonging time to local failure in patients with inoperable stage I non-small cell lung cancer.
Ethnicity, insurance status, and other factors are associated with overall survival in patients with non-small cell lung cancer.
The IASLC has published its first version of the Atlas of EGFR Testing in Lung Cancer.
The IASLC has launched guidelines for nurses and clinicians who are treating lung cancer with immunotherapy and encounter adverse events.